



Celldex Therapeutics, Inc.  
Investor Relations Department  
119 Fourth Avenue  
Needham, MA 02494-2725  
United States

Visit IR website [↗](#)  
Sign-up for email alerts [↗](#)

<b>NASDAQ: CLDX</b> <sup>1</sup>	
Last Trade:	2.44
Trade Time:	4:00 PM ET Mar 22, 2018
Change:	-0.02 <span style="color: red;">↓</span> (0.813%)
Day Range	2.40 - 2.49
52-Week Range	2.20 - 3.75
Volume	1,120,395
Market Cap. (\$M)	0.00
Shares Out (M)	0.00

<sup>1</sup> The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

## Company Profile

Celldex Therapeutics, Inc. is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Mar 7, 2018

[Celldex Provides Corporate Update and Reports Full Year 2017 Results](#)

Mar 2, 2018

[Celldex to Report Fourth Quarter and Year-End 2017 Business/Financial Results and Present at Upcoming Investor Conference](#)

Nov 30, 2017

[Celldex Therapeutics Initiates Phase 1 Study of New Product Candidate CDX-1140 in Solid Tumors](#)

Nov 17, 2017

[Celldex Therapeutics Initiates Phase 2 Combination Study of CDX-3379 and Cetuximab in Head and Neck Squamous Cell Carcinoma](#)

Nov 7, 2017

[Celldex Reports Third Quarter 2017 Results](#)

## Events [\[ View all \]](#)

There are no events to display at this time. Please check back later.

## Financials [\[ View all \]](#)

[Fourth Quarter Financial Results](#)

Mar 7, 2018

[Annual Report \(10-K\)](#)

Apr 28, 2017

[Definitive Proxy Statement](#)

Nov 7, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 9, 2017

[Quarterly Report \(10-Q\)](#)